Wockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...

Cipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia a...

"As part of this agreement, Cipla will be responsible for distribution of the COVID-19 rapid antibody kit that will be manufactured by Mult...

In an interview with Suman Layak, Vohra explains his strategy of taking Cipla products to global markets.

Cipla said it had agreed to an exclusive deal with Serum Institute to supply vaccines to South Africa, adding a new market to their partner...

Cipla's stock surged 3.23 per cent to settle at Rs 618.60 on the BSE. In intra-day, it climbed 4.13 per cent to Rs 624.

Cipla has launched multiple respiratory products in Europe this year, and launch of some key inhalers is expected in 2015.

Pharmaceutical firm Cipla today announced commercial collaboration with UK-based S&D Pharma in the Czech Republic and Slovakia.

The maiden launch increases the possibility and visibility of subsequent launches of the company’s inhalers in other countries.

Cipla intends to launch the CE marked OneDose ReadyfusOR pre-filled with Ropivacaine under its own label into the German market late this y...

Cipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...